LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.
Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.
Real-World Evidence (#RWE) has the potential to offer significant benefit in the development of new medicines by enhancing understanding of patient populations, shortening drug development timelines and providing robust evidence on the effectiveness and safety of new treatments in real world settings.
During a recent discussion with Paul Gough, Partnership and Projects Manager at Great Ormond Street Hospital for Children NHS Foundation Trust and GOSH DRIVE, our Head of NHS Partnerships, Alistair Armstrong reflects on how the Arcturis partnership network of leading #NHS trusts and the wider ecosystem is successfully working together to realise these benefits by curating real-world datasets that support ground breaking medical research.
If you are an NHS Trust or representative interested in working with us, please reach out at info@arcturisdata.com#realworlddata#gosh#greatormondstreet#healthcareinnovation#arcturis#nhspartner
In terms of our tourists clients O what what's the environment for and the appetite for real world data at the moment? And, and how do you think they view the way that you're working with the NHS trusts? Can you tell us a bit about that? So I think, yeah, I mean the environment is certainly evolving. I think at the moment we're still at kind of a, an, a relatively early stage in terms of the acceptance of, you know, use of real world data to provide evidence to support clinical development of new medicines and therapeutics. But it's an area with exponential growth opportunity. And I think the more work that we as an organization do, but also more, the more work that the ecosystem does, not just Arcturus, but companies like us to help the NHS, you know, utilize this asset that you that you have this, this this digital patient record is key to, to taking it forward and developing the industry as a whole. And I think, you know, that it has to be recognised that we all kind of small part, you know, small pieces in a, in a very large pie. And ultimately it's about the end goal is, is that large pie. And I think if we all play our part, it will help to facilitate the the evolution of this particular space. But kind of in line with that, also there is the development of technology. There's also policy essentially, both within government, but also NHS England as a whole that is really pushing forward with this, with this agenda. The use of data to support research. Obviously there's a, there's a lot of talk about AI and the use kind of the potential for AI in terms of helping to evolve the healthcare kind of sector to deliver better productivity but deliver better patient outcomes. But I think from a real world evidence perspective, we're really at an inflection point at the moment where the work that we can do with worldwide data, where we're creating data sets that are regulatory grades that have clear provenance, where you understand how that data has been collected, how it's been transformed into a position where it can be used for research. Um, is really developing at the moment at a pace where we're starting to see real acceptance of, of this sort of work because ultimately it will help to improve, you know, the activity within the UK so. You know, if you're looking at kind of UK PLC's, you know, supporting clinical trial, you know, activity within the NHS which in the last few years has been declining, we really need to push that forward. And I think the use of reward evidence using UK data, which I think is really important here because historically data has been used from other parts of the world to kind of create a representation of what it might be in the UK. But if we can actually represent real patients from the UK and how they're being treated in line with, you know, the, the development of new drugs, it will really help. Make sure that the UK population is served well by by what we're doing. So it's absolutely an involving space, but it's evolving a really positive direction.
